55% of Asian patients versus 30% Caucasian patients are missing the allele for the CYT450 system needed for omeprazole metabolism. Thus, Asian patients may experience more complications from omeprazole use after percutanous coronary intervention. “Dual anti-platelet therapy (DAPT) with Aspirin and a Thienopyridine-derivative P2Y12 Inhibitor (commonly Clopidogrel) is mandatory after Percutaneous Coronary Intervention (PCI). H2 receptor antagonists (H2RA) or Proton Pump Inhibitors (PPI) are prescribed to reduce gastrointestinal bleeding risk.”
Yew MS, Yeo PSD, Ong JLP et al.
CRT-133 Omeprazole Use is Associated with Increased Cardiovascular Complications in Asian Patients on Aspirin and Clopidogrel After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions
Volume 7, Issue 2 Supplement, February 2014
DOI: 10.1016/j.jcin.2014.01.034, accessed 21 September 2018.